Kämmenen kalvokutistuman hoitostrategiat: satunnaistettu, kontrolloitu monikeskustutkimus

DupuytrEn Treatment EffeCtiveness Trial (DETECT): a protocol for prospective, randomized, controlled, outcome assessor-blinded, three armed parallel 1:1:1, multicenter trial comparing efficacy and cost effectiveness of collagenase clostridium histolyticum, percutaneous needle fasciotomy and limited fasciectomy as a short and long term treatment strategy in mild or moderate Dupuytren’s contracture

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2016-005215-41-FI

Enrollment

Unknown

Registered

2017-04-07

Start date

2017-05-05

Completion date

Unknown

Last updated

2017-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 19.1 Level: PT Classification code 10013872 Term: Dupuytren's contracture System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders

Interventions

Trade Name: Xiapex Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Clostridium histolyticum-kollagenaasi CAS Number: 9001-12-1 Other descriptive name: COLLAGENA

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 211 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 67

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Finland

Contacts

Public ContactOlli Leppänen

Olli Leppänen

olli.leppanen@uta.fi+3583311611

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026